Literature DB >> 3288868

The crisis in clinical cancer research. Third-party insurance and investigational therapy.

K Antman1, L E Schnipper, E Frei.   

Abstract

Entities:  

Mesh：

Year:  1988        PMID： 3288868     DOI： 10.1056/NEJM198807073190109

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

Review 1.  Optimising the economic efficiency of drug studies.

Authors:  M E Kitler
Journal:  Pharmacoeconomics       Date:  1992-11       Impact factor: 4.981

2.  Designing clinical protocols for optimal use: measuring attributes of treatment and cancer control trials.

Authors:  J E Veney; W P Kory; J M Barnsley; A D Kaluzny
Journal:  J Med Syst       Date:  1991-12       Impact factor: 4.460

3.  Cost: the new factor clinical cancer investigators must learn to consider.

Authors:  M Markman
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

4.  Phase 1 trials of intensive antineoplastic therapy: a need for a critical reassessment of who should be treated.

Authors:  M Markman
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.